公开(公告)号：US20190316068A1

公开(公告)日：2019-10-17

申请号：US16381866

申请日：2019-04-11

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Christopher S. CHEN ,  Rebeccah LUU ,  Anant CHOPRA

IPC分类号： C12M3/00 ,  C12N5/077 ,  C12N5/00 ,  C12N5/074 ,  C12N5/0735 ,  C12M1/34

摘要： Described herein are a system, device, methods and compositions related to generating 3-dimensional cardiac tissues. Also described herein are a system, device, and methods of maturing 3-dimensional cardiac tissues and maintaining their viability in culture.

公开(公告)号：US10386368B2

公开(公告)日：2019-08-20

申请号：US15902614

申请日：2018-02-22

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Darrell N. Kotton ,  Finn Hawkins

IPC分类号： G01N33/569 ,  A61K35/42 ,  C12N5/071 ,  A61K9/00

摘要： Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

公开(公告)号：US20190218614A1

公开(公告)日：2019-07-18

申请号：US16249104

申请日：2019-01-16

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Kenneth WALSH ,  Soichi SANO ,  Kosei OSHIMA

IPC分类号： C12Q1/6883

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156

摘要： As demonstrated herein, a preferential and progressive expansion of a subset of hematopoietic cells bearing somatic mutations in one or more HSC cardiometabolic driver genes leads to pro-inflammatory signaling at multiple levels. Accordingly, provided herein are compositions, methods, and assays for modulating a HSC cardiometabolic driver gene mutation-mediated proinflammatory activity.

公开(公告)号：US20190153106A1

公开(公告)日：2019-05-23

申请号：US16263202

申请日：2019-01-31

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Nelson Ruiz-Opazo ,  Victoria L.M. Herrera ,  Francis Joseph Carr

IPC分类号： C07K16/28

摘要： Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.

公开(公告)号：US10275656B2

公开(公告)日：2019-04-30

申请号：US15526670

申请日：2015-11-20

申请人： Trustees of Boston University

发明人： Gregory D. Castanon ,  Venkatesh Saligrama ,  Ziming Zhang ,  Yuting Chen

IPC分类号： G06K9/62 ,  G06K9/00 ,  G06F17/30 ,  G06K9/46

摘要： One embodiment of the present solution is a relationship-based video server system. The server system is programmed to provide a platform for large scale video search based on relationships between objects in video segments, and the platform executes search based on probabilistically discriminative objects and relationships.

公开(公告)号：US10258600B2

公开(公告)日：2019-04-16

申请号：US15059911

申请日：2016-03-03

申请人： Trustees of Boston University ,  Northeastern University ,  Boston Medical Center Corporation

发明人： David H. Sherr ,  Michael Pollastri ,  Jennifer Schlezinger ,  Sarah Haigh Molina ,  Scott Schaus ,  Joshua Robert Giguere

IPC分类号： A61K31/352 ,  C07D311/22 ,  C07D407/04 ,  A61K31/35 ,  A61K45/06

摘要： Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

公开(公告)号：US20190092865A1

公开(公告)日：2019-03-28

申请号：US16026467

申请日：2018-07-03

申请人： Trustees of Boston University

发明人： Nelson Ruiz-Opazo ,  Victoria L.M. Herrera

IPC分类号： C07K16/28 ,  A61K49/22 ,  G01N33/574 ,  A61M37/00 ,  C07K16/30 ,  A61K47/55 ,  A61K38/18 ,  A61K39/00

摘要： Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.

公开(公告)号：US20190054120A1

公开(公告)日：2019-02-21

申请号：US16102905

申请日：2018-08-14

申请人： TRUSTEES OF BOSTON UNIVERSITY ,  BOSTON MEDICAL CENTER CORPORATION

发明人： Xuemei Zhong ,  Joyce Wong

IPC分类号： A61K35/17 ,  A61K47/24 ,  C12N5/0781 ,  C12N5/09 ,  A61K47/69 ,  C12N5/16

摘要： The technology described herein relates, at least in part, to compositions comprising and methods for isolating and enriching natural IgM-producing phagocytic B (NIMPAB) cells and methods of producing IgM antibodies using such cells, as well as uses of the antibodies produced by the methods for the prevention and treatment of diseases wherein immunotherapy with such natural IgM antibodies and their derivatives can be useful.

公开(公告)号：US10188795B2

公开(公告)日：2019-01-29

申请号：US15380516

申请日：2016-12-15

申请人： Trustees of Boston University ,  The General Hospital Corporation

发明人： Firas El-Khatib ,  Edward Damiano ,  Steven J. Russell

IPC分类号： A61M5/172 ,  G16H50/50 ,  A61M5/142 ,  G06F19/00 ,  A61M5/14

摘要： Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).

公开(公告)号：US10184888B2

公开(公告)日：2019-01-22

申请号：US15515958

申请日：2015-10-01

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. ,  Boston University

发明人： Wolfgang Schade ,  Jörg Burgmeier ,  Anna Lena Baumann ,  Björn Reinhard

IPC分类号： G01N21/41 ,  G01N21/552 ,  G01N21/77 ,  G01V1/18

摘要： A device for determining a refractive index may be provided. The device including at least one waveguide having a core and a cladding surrounding the core, the cladding being at least partly removed in at least one first longitudinal portion and the core including at least one fiber Bragg grating in at least one second longitudinal portion. A method for determining a refractive index or a pressure change in a fluid may also provided. The method may include at least one waveguide having a core and a cladding surrounding the core, the cladding being at least partly removed in at least one longitudinal portion. A method for producing such a device may also be provided.